Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15341460 | 1.00 | EPHX1 (0.46) | EPHX1TDP1CA12CA1CA2 | |
| SCHEMBL1859283 | 0.98 | EPHX1 (0.43) | EPHX1TDP1CA12CA1CA2 | |
| SCHEMBL1865098 | 0.93 | CTSK (0.42) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5493650 | 0.86 | TDP1 (0.59) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5498803 | 0.86 | TDP1 (0.42) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20464123 | 0.85 | CA1 (0.43) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL7519278 | 0.84 | PAOX (0.42) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5490754 | 0.84 | HDAC4 (0.41) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL15332859 | 0.84 | TDP1 (0.41) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL5493643 | 0.84 | TDP1 (0.41) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118027137-A | Tubulysin and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3898651-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132658-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132658-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-1183230-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000075105-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999064595-A9 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | EPHX1 3994/4885TDP1 1501/4885CA12 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.